Scarica l'app Stockscreener
8.57
2.15%
0.18
Dopo l'orario di chiusura:
8.58
0.010
+0.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$8.39
Aprire:
$8.55
Volume 24 ore:
224.80K
Relative Volume:
0.98
Capitalizzazione di mercato:
$161.42M
Reddito:
$107.35M
Utile/perdita netta:
$6.84M
Rapporto P/E:
24.26
EPS:
0.3532
Flusso di cassa netto:
$14.64M
1 W Prestazione:
+6.59%
1M Prestazione:
+6.59%
6M Prestazione:
+30.64%
1 anno Prestazione:
-51.31%
Intervallo 1D:
$8.31
$8.76
Intervallo di 1 settimana:
$7.69
$8.86
Portata 52W:
$4.54
$22.25
Optimizerx Corp Stock (OPRX) Company Profile
Nome
Optimizerx Corp
Settore
Industria
Telefono
248-651-6558
Indirizzo
260 CHARLES STREET, WALTHAM, MI
Compare OPRX vs VEEV, TEM, TXG, BTSG, HNGE
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OPRX
Optimizerx Corp
|
8.57 | 151.44M | 107.35M | 6.84M | 14.64M | 0.3532 |
VEEV
Veeva Systems Inc
|
273.33 | 45.44B | 3.32B | 941.65M | 1.64B | 5.6161 |
TEM
Tempus Ai Inc
|
76.63 | 15.43B | 1.36B | -302.91M | -219.93M | -1.7182 |
TXG
10 X Genomics Inc
|
93.50 | 11.17B | 638.78M | -22.66M | 122.18M | -0.1744 |
BTSG
Brightspring Health Services Inc
|
60.25 | 11.20B | 13.65B | 169.86M | 412.12M | 1.0758 |
HNGE
Hinge Health Inc
|
97.67 | 7.71B | 646.34M | -512.40M | 202.76M | -6.6871 |
Optimizerx Corp Stock (OPRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-08 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-12-20 | Iniziato | Stephens | Equal-Weight |
| 2024-07-25 | Ripresa | B. Riley Securities | Buy |
| 2024-04-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-01-03 | Iniziato | Barclays | Equal Weight |
| 2023-02-02 | Ripresa | B. Riley Securities | Buy |
| 2022-11-01 | Iniziato | Stifel | Buy |
| 2022-07-15 | Iniziato | SVB Leerink | Outperform |
| 2021-10-18 | Ripresa | B. Riley Securities | Buy |
| 2021-04-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-01-03 | Iniziato | William Blair | Outperform |
Mostra tutto
Optimizerx Corp Borsa (OPRX) Ultime notizie
OptimizeRx stock gets a higher USD 11.00 price target - AD HOC NEWS
OPTIMIZERx Corp (NASDAQ: OPRX) Share Price, OPRX Stock News, OPRX Share Price & Updates - kalkine.ca
Squarepoint Ops LLC Sells 132,507 Shares of OptimizeRx Corp. $OPRX - MarketBeat
OptimizeRx Expands Authenticated HCP Reach on The Trade Desk - MarTech Cube
Will OPRX's OpenPath Deal Help TTD Capture More Healthcare Ad Dollars? - Zacks Investment Research
Will OPRX's OpenPath Deal Help TTD Capture More Healthcare Ad Dollars? - TradingView
OptimizeRx Corporation (OPRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
OptimizeRx Partners With The Trade Desk To Widen Its Healthcare Ad Network - Asianet Newsable
OptimizeRx Corp. And The Trade Desk Bring Net New Authenticated HCP Reach To The Trade Desk Through OpenPath - marketscreener.com
OptimizeRx Brings Net New Authenticated HCP Reach to The Trade Desk Through OpenPath - Stock Titan
OptimizeRx Corp. (NASDAQ:OPRX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
OptimizeRx Expands Natural Language Audience Builder to Unify HCP and DTC Audience Intelligence - The Manila Times
One prompt now builds patient and doctor audiences. OptimizeRx expanded the tool. - Stock Titan
OptimizeRx to Participate in the 10th Annual Lake Street Best Ideas Growth Conference - marketscreener.com
A 10th annual growth conference is set for New York, with OptimizeRx taking part. - Stock Titan
Optimizerx Stock Price Forecast. Should You Buy OPRX? - StockInvest.us
OptimizeRx (OPRX) insider stock withheld for taxes - Stock Titan
OptimizeRx appoints Troy Sarich as company advisor By Investing.com - Investing.com Canada
OptimizeRx appoints Troy Sarich as company advisor - investing.com
OptimizeRx Appoints Former Johnson & Johnson Executive Troy Sarich as Company Advisor - Quiver Quantitative
OptimizeRx Appoints Pharma Commercialization and AI Expert Troy Sarich as Company Advisor - Yahoo Finance UK
OptimizeRx Corp. (NASDAQ:OPRX) Given Average Rating of "Moderate Buy" by Analysts - marketbeat.com
OptimizeRx (NASDAQ: OPRX) COO keeps 25,187 shares after RSU tax withholding - Stock Titan
OptimizeRx (OPRX) records insider share trade - Stock Titan
OPRX | OptimizeRx Corporation Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
OptimizeRx (OPRX) Q2 2026 Earnings Call Transcript - AOL.com
OptimizeRx (OPRX) EPS and Revenue: Profit Per Share Clears Its Benchmark in the Current Update; Closing Move - vinanet.vn
OptimizeRx Corp (OPRX) Stock News Today - TradingKey
symbol__ Stock Quote Price and Forecast - CNN
OptimizeRx (OPRX) Slips to $8.72 as Shares Consolidate Near Range MidpointInverse ETF Flow - vinanet.vn
OptimizeRx Corp (OPRX) gains 6.7% institutional holder in Kennedy Capital - Stock Titan
Conferencia de resultados del segundo trimestre fiscal de 2026 de OptimizeRx (OPRX): Reitera previsiones mientras los ingresos caen un 30% - TradingKey
OptimizeRx (NASDAQ:OPRX) Stock Price Expected to Rise, Citizens Jmp Analyst Says - marketbeat.com
Citizens raises OptimizeRx stock price target on macro stability By Investing.com - Investing.com Nigeria
Citizens raises OptimizeRx stock price target on macro stability - Investing.com
Renaissance Technologies LLC Has $1.36 Million Stock Position in OptimizeRx Corp. $OPRX - MarketBeat
OptimizeRx (OPRX) Earnings Call zu Q2 des Geschäftsjahres 2026: Prognose bestätigt, während der Umsatz um 30 % sinkt - TradingKey
OptimizeRx (OPRX) Fiscal Q2 2026 Earnings Call: Guidance Reaffirmed as Revenue Falls 30% - TradingKey
Stifel cuts OptimizeRx stock price target on revenue headwinds By Investing.com - Investing.com Australia
OptimizeRx Reaffirms 2026 Outlook Amid Revenue Decline - The Globe and Mail
OptimizeRx (OPRX) revenue falls 21% as margins and cash flow hold - Stock Titan
Stifel cuts OptimizeRx stock price target on revenue headwinds - Investing.com
OPTIMIZERx earnings beat by $0.06, revenue topped estimates - Investing.com Nigeria
OptimizeRx Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance - The Manila Times
OptimizeRx Corp (OPRX) (Q2 2026) Earnings Call Highlights: Navigating Revenue Headwinds with ... - Yahoo! Finance Canada
OptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of Growth - Technology Magazine
OptimizeRx Q2 Earnings Call Highlights - MarketBeat
OPRX Looks 45.1% Undervalued on GF Value™ - GuruFocus
OptimizeRx Q2 adj. EPS beats estimate as sales fall 30% YoY - scanx.trade
Earnings call transcript: OptimizeRx beats Q2 2026 profit view as shares slip - Investing.com Australia
Optimizerx Corp Azioni (OPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Optimizerx Corp Azioni (OPRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Stelmakh Edward | Chief Finance & Strat Officer |
Dec 19 '25 |
Sale |
13.51 |
1,388 |
18,752 |
126,830 |
| Silvestro Stephen L | Chief Executive Officer |
Dec 19 '25 |
Option Exercise |
0.00 |
6,546 |
0 |
195,462 |
| Odence-Ford Marion | Chief Legal & Admin Officer |
Dec 19 '25 |
Option Exercise |
0.00 |
3,928 |
0 |
94,526 |
| Besch Doug | Chief Product & Tech Officer |
Dec 19 '25 |
Option Exercise |
0.00 |
1,964 |
0 |
71,536 |
| Odence-Ford Marion | Chief Legal & Admin Officer |
Oct 03 '25 |
Option Exercise |
0.00 |
6,649 |
0 |
92,550 |
| Silvestro Stephen L | Chief Executive Officer |
Oct 03 '25 |
Option Exercise |
0.00 |
6,649 |
0 |
190,536 |
| Silvestro Stephen L | Chief Executive Officer |
Oct 03 '25 |
Sale |
18.75 |
1,620 |
30,375 |
188,916 |
| Stelmakh Edward | Chief Finance & Strat Officer |
Oct 03 '25 |
Option Exercise |
0.00 |
16,623 |
0 |
127,387 |
| Besch Doug | Chief Product & Tech Officer |
Oct 03 '25 |
Option Exercise |
0.00 |
3,325 |
0 |
70,555 |
0.13%
2.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):